Intra-Cellular Therapies Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: New York NY United States (2002)

Organization Overview

First Clinical Trial
2011
NCT01499563
First Marketed Drug
2019
lumateperone (Caplyta)
First NDA Approval
2019
lumateperone (Caplyta)
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

INTRA-CELLULAR | Intra-Cellular Therapies Inc | Intra-Cellular Therapies, Inc. | INTRA-CELLULAR THERAPIES INC | Intra-Cellular Therapies, Inc. (ITI)